Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Accounts Payables · FY2024 · year ended Mar 2025
Accounts payables turns negative
FY2024 accounts payables was -$204.69K, compared with $210.28K a year earlier.
Context
- Accounts payables amounted to 3.3% of revenue in FY2024, down 0.2 pp from a year earlier.
- Accounts payables increased in 1 of the last 2 fiscal years.
- FY2024 was the lowest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2024
- (204.69K) USD
- Year-over-year change
- -197.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | (204.69K) | -197.3% |
| FY2023 | 2024-03-31 | 210.28K | +16.6% |
| FY2022 | 2023-03-31 | 180.4K | — |
Accounts Payables vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 accounts payables of $204.69K is the 7th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -197.3% is the 8th highest of 9, against a peer median of -47.4%.
- Accounts payables amounts to 3.3% of revenue for MCTA, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.19M | +142.5% | — | 3.5% | |
| LTM Mar 2026 | $8.24M | -11230.1% | — | 210.1% | |
| LTM Mar 2026 | $6.67M | +3.7% | — | — | |
| LTM Mar 2026 | $5.42M | +544.5% | +38.4% | 6.0% | |
| LTM Mar 2026 | $3.45M | -134.0% | — | 0.3% | |
| LTM Feb 2026 | $403K | +352.8% | -6.6% | 0.5% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $204.69K | -197.3% | — | 3.3% |
| LTM Mar 2026 | $26K | -98.5% | — | 0.0% | |
| LTM Mar 2026 | $22K | -101.1% | -0.4% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MCTA) | $0 | -47.4% | -0.4% | 0.4% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Net Income | (335.61K) | 821.74K | 1.2M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| Deferred Income Tax | 0 | 62.48K | 134.87K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 2.5M | (943.05K) | (1.16M) |
| Accounts Receivables | (154.02K) | (164.98K) | (44.29K) |
| Inventory | (55.87K) | 38.18K | 1.35K |
| Accounts Payables | 180.4K | 210.28K | (204.69K) |
| Other Working Capital | 2.53M | (1.03M) | (913.02K) |
| Other Non-Cash Items | 60.9K | (37.45K) | (10.89K) |
| Operating Cash Flow | 2.43M | 295.43K | 425.89K |
| Capital Expenditures | (606.19K) | (210.6K) | (287.53K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.94M) |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (606.19K) | (210.6K) | (2.23M) |
| Debt Repayment | (177.92K) | (115.85K) | 48.93K |
| Common Stock Issued | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (1.25M) | 216K | 472.37K |
| Financing Cash Flow | (1.43M) | 100.15K | 521.3K |
| Effect of Forex Changes | 5.66K | (10.51K) | (4.62K) |
| Net Change in Cash | 402.99K | 174.46K | (1.29M) |
| Free Cash Flow | 1.83M | 84.83K | 138.36K |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.